Effectively treat the pain and inflammation of canine OA and support compliance with convenient once weekly oral dosing.
Could that golden retriever struggling with their hips benefit
from Daxocox®…? And what about the owner of that spaniel that
finds daily dosing challenging…?
SIGN UP NOW
Use the stock selector to make up a product package that perfectly suits
the patients that you feel Daxocox® could help.
Or why not get a selection, so you’re ready to experience the benefits of
Daxocox® in whatever OA case comes through the door next?
What does £250 of Daxocox® look like?
x4
30KG LABRADORS
x6
22KG SPRINGER SPANIELS
x12
10KG TERRIERS
We’re confident that you have multiple patients that would benefit from the unique features of Daxocox®
88% OF OWNERS
of dogs with OA said that weekly NSAID dosing would be one of the following:
- Easier to remember
- Mean they would be less likely to miss a dose
- Would control their dog’s pain better 1
Watch how Daxocox® works
Daxocox® – a breakthrough in OA treatment
Proven to effectively treat
the pain and inflammation of canine OA2,3
Simple weekly dosing
with a flavoured tablet
Consistent plasma levels
for 7 days, thanks to its unique 7-day phasic pharmacology4
Licensed for all stages of OA5
Can be given continuously, with no risk of over-accumulation or need for mandatory treatment breaks4
Want to tell someone else about this great offer?
REFERENCES: 1. Daxocox® Pet Owner Insight Executive Summary (N=200) January 2021. 2. Internal report: DA/197/C, pending publication. 3. Salichs M., Badiella L., Sarasola P., Homedes J. (2021) Efficacy and safety of enflicoxib for treatment of canine osteoarthritis: A 6-week randomised, controlled, blind, multicentre clinical trial. Veterinary Record e949. https://doi.org/10.1002/vetr.949 4. Internal report: PK_001_2018, pending publication. 5. Daxocox® SPC
Daxocox®15mg, 30mg, 45mg, 70mg and 100mg weekly tablets for dogs. Active substance: Enflicoxib. UK POM-V, 15mg Vm 32742/5001 EU/2/21/270/001-007, 30mg Vm 32742/5002 EU/2/21/270/008-014, 45mg Vm 32742/5003 EU/2/21/270/015-021, 70mg Vm 32742/5004 EU/2/21/270/022-028, 100mg Vm 32742/5005 EU/2/21/270/029-035. Indications for use: For the treatment of pain and inflammation associated with osteoarthritis (or degenerative joint disease) in dogs. Further information can be found in the SPC, the datasheet or the pack leaflet.
USE MEDICINES RESPONSIBLY.
Terms and conditions : 1. Offer available in the United Kingdom only. 2. Animalcare reserve the right to withdraw the offer at any time. 3. Offer closes 31st December 2022. 4. Promotion and prices subject to change. 5. The initial trial offer is only available once per practice.
Daxocox® is a registered trademark of Animalcare Group Plc
Copyright ©2021 Animalcare. All rights reserved.